PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

Phase 3

Completed

Conditions: Acute Migraine

Interventions: Drug: Rimegepant 75mg Orally Disintegrating Tablets (ODT)

First Posted Date: 2022-05-12

Last Posted Date: 2024-04-26

Lead Sponsor: Pfizer

Target Recruit Count: 241

Registration Number: NCT05371652

Locations: 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳
Hebei General Hospital, Shijiazhuang, Hebei, China

and more 22 locations

A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS

Not Applicable

Completed

Conditions: Immunogenicity, Vaccine

Interventions: Biological: PCV13 PAC study

First Posted Date: 2022-05-12

Last Posted Date: 2023-10-03

Lead Sponsor: Pfizer

Target Recruit Count: 300

Registration Number: NCT05372575

Locations: 🇨🇳
Children's Hospital of Soochow University, Suzhou, Jiangsu, China

Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland

Completed

Conditions: Myeloid Leukemia

Interventions: Drug: Bosutinib

First Posted Date: 2022-05-06

Last Posted Date: 2023-04-03

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT05363488

Locations: 🇬🇧
eatson West of Scotland Cancer Centre, Glasgow, United Kingdom

A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

Completed

Conditions: Renal Cell Cancer
Renal Cell Carcinoma
Kidney Cancer
Kidney Neoplasms
Renal Cancer
Cancer of Kidney
Cancer of the Kidney

First Posted Date: 2022-05-05

Last Posted Date: 2024-09-30

Lead Sponsor: Pfizer

Target Recruit Count: 1112

Registration Number: NCT05363072

Locations: 🇫🇮
Pfizer Finland, Helsinki, Finland

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Palbociclib + an aromatase inhibitor
Drug: Aromatase inhibitor

First Posted Date: 2022-05-05

Last Posted Date: 2024-06-07

Lead Sponsor: Pfizer

Target Recruit Count: 2888

Registration Number: NCT05361655

Locations: 🇺🇸
10017, New York, New York, United States

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Phase 1

Recruiting

Conditions: Melanoma
Non-Small-Cell Lung Cancer
Thyroid Cancer
Glioma

Interventions: Drug: PF-07799933
Drug: binimetinib
Biological: cetuximab

First Posted Date: 2022-05-02

Last Posted Date: 2024-11-26

Lead Sponsor: Pfizer

Target Recruit Count: 156

Registration Number: NCT05355701

Locations: 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸
Clinical and Translational Research Center (CTRC), Aurora, Colorado, United States
🇺🇸
Clinical And Translational Research Center, Aurora, Colorado, United States

and more 39 locations

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

Phase 3

Active, not recruiting

Conditions: Vaso-occlusive Crisis
Sickle Cell Disease
Vaso-occlusive Pain Episode in Sickle Cell Disease

Interventions: Drug: Inclacumab

First Posted Date: 2022-04-27

Last Posted Date: 2024-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 123

Registration Number: NCT05348915

Locations: 🇳🇬
Aminu Kano Teaching Hospital, Kano, Nigeria
🇳🇬
Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital, Lagos, Nigeria
🇴🇲
Sultan Qaboos University Hospital, Muscat, Oman

and more 68 locations

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07284890 Treatment A
Drug: PF-07284890 Treatment B
Drug: PF-07284890 Treatment C

First Posted Date: 2022-04-27

Last Posted Date: 2024-03-15

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05349864

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07321332/ritonavir

First Posted Date: 2022-04-21

Last Posted Date: 2024-10-08

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT05339334

Locations: 🇨🇳
Huashan Hospital,Fudan University, Shanghai, Shanghai, China

A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India

Phase 4

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 13-valent pneumococcal conjugate vaccine

First Posted Date: 2022-04-14

Last Posted Date: 2024-04-26

Lead Sponsor: Pfizer

Target Recruit Count: 200

Registration Number: NCT05329259

Locations: 🇮🇳
Calcutta School of Tropical Medicine, Kolkata, WEST Bengal, India
🇮🇳
Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
🇮🇳
Jawahar Lal Nehru Medical College, Ajmer, Rajasthan, India

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy